Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler (REALITY)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00812682
First received: December 19, 2008
Last updated: January 21, 2011
Last verified: January 2011

December 19, 2008
January 21, 2011
September 2006
Not Provided
  • Patient satisfaction with the adjustable maintenance dosing schedule [ Time Frame: Throughout the study ] [ Designated as safety issue: No ]
  • Physicians' satisfaction with the adjustable maintenance dosing schedule [ Time Frame: Throughout the study ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00812682 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler
Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler

This study will evaluate the perception of the physicians and the patients about the approved adjustable dosing of Symbicort® 160/4,5. Symbicort maintenance dose will be adjusted up and down within the approved dose range of 1x2 - 4x2 inhalations per day, to the level of asthma symptoms. Patients and physicians perception of this new dosing schedule will be evaluated by means of questionnaires completion and direct questioning.

Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Primary Care

Perception of Physicians & Patients of AMD
Drug: Symbicort
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
217
August 2007
Not Provided

Inclusion Criteria:

  • Minimum of 6 months history of asthma and treatment with an inhaled corticosteroids for at least 3 months prior to visit 1 and/or a history of short term variation in airway function and asthma symptoms responding promptly to convent
  • Patients where use of a combination (inhaled corticosteroid and long acting beta2-agonist is appropriate, i.e. not controlled on inhaled corticosteroids alone).

Exclusion Criteria:

  • Asthma exacerbation requiring oral corticosteroid treatment in the four weeks prior to visit 1
  • Upper Respiratory Tract Infection in the previous four weeks
  • Severe cardiovascular disease or other significant concomitant disease, which may interfere with the conduct of the study.
  • Women enrolled in the trial should not be planning pregnancy and should be taking adequate contraceptive measures where appropriate.
  • Previous enrollment in a clinical study
  • Known or suspected hypersensitivity to budesonide, formoterol or inhaled lactose
Both
12 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00812682
D5890L00021
No
Panagiotis Pontikis, MD, Medical & Regulatory Affairs Director, AstraZeneca Greece, AstraZeneca S.A., Greece
AstraZeneca
Not Provided
Study Director: Panagiotis Pontikis, MD Medical & Regulatory Affairs Director, AstraZeneca Greece: 4
AstraZeneca
January 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP